Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 diseases that affect the lung interstitium. These conditions, characterized by varying degrees of inflammation and fibrosis, present a diagnostic and therapeutic challenge for healthcare professionals due to their complex etiology and clinical presentation.
ILDs can be classified into idiopathic and secondary forms. The idiopathic forms, including idiopathic pulmonary fibrosis (IPF), are of unknown cause. Secondary ILDs can occur due to systemic diseases, occupational exposure, drugs, and radiation. Understanding the cause is crucial, as it greatly influences the management and prognosis of the disease.
Patients with ILDs often present with non-specific symptoms such as dyspnea and cough. The diagnosis of ILDs involves a comprehensive assessment including clinical evaluation, radiological imaging, and sometimes, lung biopsy. High-resolution computed tomography (HRCT) is the gold standard imaging technique for ILDs, providing detailed information about the lung architecture.
The management of ILDs is complex and depends on the underlying cause. For IPF, antifibrotic drugs such as pirfenidone and nintedanib have shown to slow disease progression. In secondary ILDs, treating the underlying cause is paramount. Lung transplantation may be an option for selected patients with advanced disease. The prognosis of ILDs varies widely, with IPF having the worst survival rates.
Interstitial lung diseases are a diverse group of disorders with a complex etiology and clinical presentation. Accurate diagnosis and appropriate management are key to improving patient outcomes. As healthcare professionals, staying updated on the latest advancements in the field is vital to provide optimal care to patients with these challenging conditions.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation